Tag Europe

Navamedic: Two first generic drugs launched

Oct12

Navamedic ASA (OSE: NAVA), the Norwegian pharmaceutical products company, todayannounced the successful launch of its two first generic pharmaceuticalproducts. The launch is an important milestone in the development of Navamedic’snew Generics Business Area.Mycophenolate Mofetil (MMF) is an immunosuppressant being used by patients whohave undergone organ transplants. The product can replace Roche’s CellCept andthe market available […]

BUYINS.NET: MEDICAL INSTRUMENTS Stocks Expected To Be Up After Top Correlated Stocks Fire Buy Signals.

Oct12

BUYINS.NET / http://www.squeezetrigger.com is monitoring the top most highly correlated MEDICAL INSTRUMENTS stocks and the majority have fired a Buy signal as of today. C.R. BARD INC (NYSE:BCR), BAXTER INTERNATIONAL INC (NYSE:BAX), DENTSPLY INTERNATIONAL INC (NASDAQ:XRAY), INTEGRA LIFESCIENCES HOLDING (NASDAQ:IART), BECTON DICKINSON AND CO (NYSE:BDX), THERMO FISHER SCIENTIFIC INC (NYSE:TMO) are all expected to be […]

Sembiosys and Tasly Pharmaceuticals Sign Multi-Product Commercialization and Platform Collaboration Agreement

Oct11

One of China's Largest Pharmaceutical Companies to Commercialize SemBioSys' Plant-Based Manufacturing Technology in Global Joint VentureCALGARY, Oct. 11, 2011 /PRNewswire/ – SemBioSys Genetics Inc. (TSX:SBS), today announced that it has signed a product and platform development collaboration agreement (the "Agreement") with Tasly Pharmaceuticals, Ltd ("Tasly") of Tianjin China and its wholly owned subsidiary Tasly U.S. […]

Significant Reduced Loss of Brain Volume in Multiple Sclerosis Patients Treated with COPAXONE

Oct11

Five-year Study Findings Published in the Journal of the Neurological Sciences JERUSALEM, Israel(BUSINESS WIRE) Results from a five-year study of treatment-nave patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies (DMTs). Though all […]

U.S. Federal Trade Commission Clears Teva’s Acquisition of Cephalon

Oct7

JERUSALEM & FRAZER, Pa.(BUSINESS WIRE) Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Cephalon, Inc. (NASDAQ: CEPH) announced today that the U.S. Federal Trade Commission (“FTC”) has accepted the proposed consent order in connection with the pending acquisition of Cephalon by Teva and granted early termination of the Hart Scott Rodino waiting period. Under the consent […]

Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial

Sep19

ANN ARBOR, Mich., Sept. 19, 2011 /PRNewswire/ Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that the 150th patient has been enrolled in the randomized, double-blind, placebo-controlled, multi-center clinical trial of its Trimesta? (oral estriol) drug candidate for relapsing-remitting multiple sclerosis (MS) in women, per […]

BUYINS.NET: UNH, NEU, RCI, CMS, MSSR, SBUX Expected to Trade Up Short Term

Sep15

BUYINS.NET / http://www.squeezetrigger.com is monitoring top equities trading strategies and these stocks are the most likely to trade Up in the coming weeks. UNITEDHEALTH GROUP INC (NYSE:UNH), NEWMARKET CORP (NYSE:NEU), ROGERS COMMUNICATIONS INC-B (NYSE:RCI), CMS ENERGY CORP (NYSE:CMS), MCCORMICK & SCHMICK’S SEAFOO (NASDAQ:MSSR), STARBUCKS CORP (NASDAQ:SBUX) are all expected to go Up as Bullish signals […]

Unilife Develops Proprietary Range of Auto-Injectors for Patient Self-Administration of Injectable Drugs

Sep14

Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) announced the development of a unique proprietary range of auto-injectors for the self-administration of injectable drugs by patients outside of healthcare facilities (see also Therapeutics).Developed for use in conjunction with Unifill prefilled syringes, Unifill Auto-Injectors are compact in size and enable patients to inject a […]

European Fine Chemicals Group Ratifies FDA’s Proposed Generic Drug User Fees Act (GDUFA)

Sep10

BRUSSELS, September 10, 2011 /PRNewswire/ The Board of the European Fine Chemicals Group (EFCG) is delighted to announce that today it agreed to ratify the proposal of the US Food and Drug Administration (FDA) to put forward a legislative package, designed with the help of EFCG and US industry representatives, to deliver into US law […]

European Fine Chemicals Group Ratifies FDA’s Proposed Generic Drug User Fees Act (GDUFA)

Sep9

BRUSSELS, September 9, 2011 /PRNewswire/ The Board of the European Fine Chemicals Group (EFCG) is delighted to announce that today it agreed to ratify the proposal of the US Food and Drug Administration (FDA) to put forward a legislative package, designed with the help of EFCG and US industry representatives, to deliver into US law […]